Neoadjuvant Sacituzumab Govitecan Plus Pembrolizumab in Resectable Non-Small Cell Lung Cancer
Clinical trial NCT06055465 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT06055465
- Sponsor
- Chinese University of Hong Kong
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2024-02-28
- Primary completion
- 2028-12-30
- Enrollment
- 37
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.